SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. [electronic resource]
Producer: 20171211Description: 3844-3850 p. digitalISSN:- 1527-7755
- Aged
- Benzamides -- administration & dosage
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Janus Kinase Inhibitors -- administration & dosage
- Male
- Maximum Tolerated Dose
- Middle Aged
- Nitriles
- Patient Safety
- Primary Myelofibrosis -- drug therapy
- Prognosis
- Pyrazoles -- administration & dosage
- Pyrimidines -- administration & dosage
- Retreatment
- Risk Assessment
- Survival Analysis
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.